Streetbeat News

Regulatory

THAR

Tharimmune, Inc. (NASDAQ:THAR) shares surged over 100% after receiving positive feedback from the European Medicines Agency (EMA) on its TH104 clinical program for treating pruritus in primary biliary cholangitis. The EMA approved the design of the Phase 2 study and provided guidance for Phase 3. Tharimmune plans to start a Phase 2 trial soon, with results expected in 2025.

Portfolio Pulse from Dylan Berman

October 30, 2024 | 4:31 pm

TGL

Treasure Global has amended its partnership agreement with Credilab, changing the profit-sharing ratio from 1/3 to 1/2. This amendment has been filed with the SEC as a supplement to the original 8-K filing.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 4:19 pm

GRFS

Grifols shares are trading higher following FDA approval for its fibrin sealant solution to treat surgical bleeding in pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 4:17 pm

PDD

Temu is set to face an EU investigation regarding its handling of illegal product sales. This scrutiny could impact its parent company, PDD Holdings, which is listed in the US.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:44 pm

THAR

Tharimmune shares rose following positive feedback from the EMA on its TH104 clinical program. The EMA approved the design of the Phase 2 study and provided guidance for a future Phase 3 study.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:23 pm

SMCI

Super Micro Computer Inc (NASDAQ:SMCI) shares plummeted after Ernst & Young resigned as the company's auditor due to governance and transparency concerns. The resignation occurred before any financial reports were issued, and a special committee is reviewing the issues raised. Despite the resignation, Super Micro does not anticipate restating any financial reports.

Portfolio Pulse from Adam Eckert

October 30, 2024 | 1:43 pm

CPHD

RHHBY

The World Health Organization (WHO) has expanded its emergency use list for Mpox diagnostics by adding Cepheid's Xpert Mpox PCR test and Roche's Cobas MPXV assay as PCR-based gold standard options.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:25 pm

SPY

VGK

The UK plans to freeze fuel duty next year and increase the tax on private equity carried interest to 32%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:21 pm

DWTX

Dogwood Therapeutics has regained compliance with Nasdaq's listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:16 pm

IMNN

IMUNON is set to present Phase 2 data of its IMNN-001 at the SITC 39th Annual Meeting. The company has also announced an FDA End-of-Phase 2 meeting to discuss the Phase 3 trial, expected to start in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:13 pm